Subject(s)
Forecasting/methods , Legislation, Medical/trends , Licensure, Medical/economics , Financial Management/legislation & jurisprudence , Humans , Insurance Coverage/legislation & jurisprudence , Liability, Legal , Missouri , Nurses/legislation & jurisprudence , Nurses/organization & administration , Prescription Drug Monitoring Programs/legislation & jurisprudence , Tanning/legislation & jurisprudence , Tanning/trendsSubject(s)
Confidentiality/legislation & jurisprudence , Licensure, Medical/legislation & jurisprudence , Medicaid/legislation & jurisprudence , Physician-Patient Relations , Telemedicine/legislation & jurisprudence , Humans , Iowa , Naloxone/therapeutic use , Narcotic Antagonists/therapeutic use , Politics , Primary Health Care , Societies, Medical , Tanning/instrumentation , Tanning/legislation & jurisprudence , United States , WorkforceABSTRACT
BACKGROUND: Chromium-tanned leather articles currently constitute the most important cause of contact allergy to chromium in Denmark. A regulation on the content of hexavalent chromium in leather was adopted in November 2013 by the EU member states. OBJECTIVES: To characterize patients with chromium allergy and their disease, to serve as a baseline for future studies on the potential effect of the new regulation on chromium in leather. METHODS: A questionnaire case-control study was performed on 155 dermatitis patients with positive patch test reactions to potassium dichromate and a matched control group of 621 dermatitis patients. Comparisons were made by use of a χ(2) -test and the Mann-Whitney U-test. Logistic regression analyses were used to test for associations. RESULTS: Sixty-six per cent of chromium-allergic patients had a positive history of contact dermatitis caused by leather exposure. They had a significantly lower quality of life (p < 0.001), a higher prevalence of dermatitis during the last year (p = 0.008), a higher use of medication during the past 12 months (p = 0.001) and a higher prevalence of sick leave (p = 0.007) than patients in the control group. CONCLUSIONS: Chromium-allergic patients have more severe and more chronic contact dermatitis. Their primary chromium exposure comes from leather articles.
Subject(s)
Chromium/adverse effects , Dermatitis, Allergic Contact/diagnosis , Dermatitis, Allergic Contact/etiology , Tanning/legislation & jurisprudence , Adult , Aged , Aged, 80 and over , Case-Control Studies , Denmark , Dermatitis, Occupational/diagnosis , Dermatitis, Occupational/etiology , Female , Humans , Male , Middle Aged , Occupational Exposure/adverse effects , Patch Tests/methods , Potassium Dichromate , Quality of Life , Severity of Illness Index , Surveys and Questionnaires , Young AdultABSTRACT
Malignant melanoma (MM) and non-melanoma skin cancer (NMSC) are increasingly common and both can be fatal. In 2009 the World Health Organization (WHO) classified the whole ultraviolet spectrum and tanning beds as carcinogenic to humans, placing them in the same category as asbestos and tobacco. Despite this, the trend for indoor tanning continues. A growing body of evidence has now associated indoor tanning with an increased risk of MM and NMSC. As a result, there has been an upsurge in regulations in the tanning industry ranging from age restrictions to complete bans on commercial tanning. This article examines the evidence and strengthens the case for a complete ban of a recognised modifiable risk factor for cutaneous malignancy.
Subject(s)
Carcinoma, Basal Cell/epidemiology , Carcinoma, Squamous Cell/epidemiology , Melanoma/epidemiology , Neoplasms, Radiation-Induced/epidemiology , Skin Neoplasms/epidemiology , Tanning , Ultraviolet Rays/adverse effects , Beauty Culture , Carcinoma, Basal Cell/etiology , Carcinoma, Squamous Cell/etiology , Humans , Melanoma/etiology , Nails , Neoplasms, Radiation-Induced/etiology , Risk Factors , Skin Neoplasms/etiology , Tanning/legislation & jurisprudenceABSTRACT
Aiming to minimize skin cancer risk and other health drawbacks of tanning beds, the U.S. Food and Drug Administration proposed new rules to increase regulation of the devices and to require warning labels recommending increased screening for cancer.